- Home
- CHPT vs KLRS Comparison
CHPT vs KLRS Comparison
Compare CHPT & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHPT | KLRS |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.1M | 132.8M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHPT | KLRS |
|---|---|---|
| Price | $6.14 | $6.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $9.67 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 490.5K | 71.5K |
| Earning Date | 06-03-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $411,224,000.00 | N/A |
| Revenue This Year | $4.18 | N/A |
| Revenue Next Year | $16.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $2.14 |
| 52 Week High | $12.62 | $11.88 |
Technical Indicators
Market Signals| Indicator | CHPT | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 63.60 | 46.11 |
| Support Level | $5.60 | $4.35 |
| Resistance Level | $6.73 | $7.18 |
| Average True Range (ATR) | 0.35 | 0.64 |
| MACD | 0.19 | 0.14 |
| Stochastic Oscillator | 83.01 | 67.37 |
Price Performance
Historical ComparisonAbout CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.